COMMUNIQUÉS West-GlobeNewswire

Tilray Shifts Cultivation of its Flagship Canadian Cannabis Brand and Strain, Good Supply Jean Guy, to Masson-Angers Facility in Québec
02/04/2025
MASSON-ANGERS, Quebec, April 02, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of beverage, cannabis [...]
Tilray Transfère la Culture de Sa Marque et de Sa Variété Canadienne Emblématique, Good Supply Jean Guy, à son Installation de Masson-Angers au Québec
02/04/2025
MASSON-ANGERS, Québec, 02 avr. 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY), un leader mondial des biens de consommation, de l’industrie du cannabis, des boissons et du bien- [...]
Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors
02/04/2025
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today [...]
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
02/04/2025
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer’s disease recently published in The Journal of Prevention of Alzheimer's Disease NEWTON, Mass., April 02, 2025 (GLOBE [...]
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
02/04/2025
During the first 16 weeks of the Extension phase of the RewinD-LB clinical study neflamapimod slowed clinical progression compared to controls, as assessed by Clinical Dementia Rating Sum of Boxes (CDR-SB) and Clinical [...]
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
02/04/2025
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease Active immunotherapy with ACI-7104.056 induces high anti-a-synuclein (a-syn) [...]
The Ensign Group Adds Two Operations in California
02/04/2025
SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and provide skilled nursing and senior [...]
Aclarion Announces Expansion to Santa Monica with Medical Imaging Center of Southern California
02/04/2025
MICSC are leaders in Los Angeles providing MRI and Diagnostic Imaging services MICSC expands access to Nociscan beyond Beverly Hills now available in Santa Monica BROOMFIELD, Colo., April 02, 2025 (GLOBE NEWSWIRE) -- [...]
Former EPA Flint Emergency Coordinator Expands Groundbreaking Drinking Water Training Program
02/04/2025
Applying Lessons Learned from the Flint Water Crisis to Strengthen Safe Drinking Water Efforts Nationwide CHICAGO, April 02, 2025 (GLOBE NEWSWIRE) -- Environmental & Public Health International (EPHI), an emerging [...]
The Ensign Group Purchases Two Facilities in Washington
02/04/2025
SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
02/04/2025
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
The Ensign Group Expands in California
02/04/2025
SAN JUAN CAPISTRANO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
02/04/2025
Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive care, oncology and [...]
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)
02/04/2025
CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemia Final European Commission decision expected by June 2025; [...]
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
02/04/2025
Number of patients reached in 2024 jumps 8% to 66 million R&D investments rise to EUR 6.2 billion, 23.2% of group net sales Company prepares new product launches starting in 2025 Boehringer Ingelheim today announced [...]
ENA Respiratory Announces Publication Supporting the Potential of its Novel Intranasal Therapy INNA-051 to Reduce the Impact of Viral Respiratory Infections in Older Adults
02/04/2025
Clinical studies demonstrated that INNA-051’s natural defence boosting mechanism is effective in older adults Administration of INNA-051 to older adults (65 years old) in a Phase 1 study was well-tolerated and increased [...]
CMR Surgical secures more than $200M to accelerate growth
02/04/2025
CMR Surgical has closed a financing round of more than $200 million, backed by existing investors and new investor Trinity Capital The latest funding will fuel the global commercialisation of its Versius Surgical [...]
Press Release Biocartis NV: Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay
02/04/2025
PRESS RELEASE 02/04/2025, 07:00 CEST Biocartis Announces Launch of the Brand-New Idylla™ POLE-POLD1 Mutation Assay Mechelen, Belgium, 02 April 2025 – Biocartis NV (“Biocartis”), an innovative molecular diagnostics [...]
Zelluna ASA [ZLNA]: Annual Report 2024
02/04/2025
Oslo, Norway, 02 April, 2025 - Zelluna ASA, a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces that the Board of Directors of [...]

Pages